Funda Meric-Bernstam

Molecular Biology · 2008–2023

A researcher in the Science corpus: 21 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 279 citations into it

Whom Funda Meric-Bernstam trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. K. Inoki

Who trusts Funda Meric-Bernstam overall

1. Ryuji Hamamoto
2. K. Courtney

Papers from Funda Meric-Bernstam's perspective

Ordered by how strongly the researchers Funda Meric-Bernstam trusts endorse each paper. Same corpus, a different order for every researcher.

1. TSC2 mediates cellular energy response to control cell growth and survival. (Cell)
2. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. (Genes & Development)
3. Metformin and reduced risk of cancer in diabetic patients (British medical journal)
4. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
5. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
6. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin (Science)
7. Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
8. Signatures of mutational processes in human cancer (Nature)
9. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
10. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin (Diabetes Care)

Their papers

• Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing (2014) — 1,019 citations
• Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) — 792 citations
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009) — 880 citations
• Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) — 2,007 citations
• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (2018) — 2,224 citations
• Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) — 375 citations
• Targeting the PI3K pathway in cancer: are we making headway? (2018) — 921 citations
• Targeting the mTOR signaling network for cancer therapy. (2009) — 666 citations
• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial (2023) — 696 citations
• Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. (2023)
• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) — 692 citations
• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) — 1,018 citations
• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) — 833 citations
• Pathogenic germline variants in 10,389 adult cancers (2018) — 734 citations
• HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) — 709 citations
• The Immune Landscape of Cancer (2018) — 4,752 citations
• Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) — 2,663 citations
• Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer (2014) — 595 citations
• PD-L1 Expression in Triple Negative Breast Cancer (2014) — 1,170 citations
• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013) — 668 citations